<DOC>
	<DOCNO>NCT01825369</DOCNO>
	<brief_summary>Infants congenital heart disease increase pulmonary blood flow alter carnitine homeostasis associate clinical outcome ; L-carnitine treatment attenuate alteration improve clinical outcome . The investigator pilot trial assess safety pharmacokinetics perioperative IV L-carnitine administration patient . To end , pilot clinical trial propose . Infants ventricular septal defect atrioventricular septal defect undergo complete surgical repair receive L-carnitine ( 25 , 50 , 100 mg/kg , IV ) prior cardiopulmonary bypass ( CPB ) 2hr CPB . Carnitine level measure CPB , 0.5 , 1.5 , 3 , 5 , 9 , 12 , 24h second dose . The safety , pharmacokinetic profile , feasibility , effect L-carnitine administration biochemical parameter , well clinical outcome determine . The investigator expect pilot provide data need proceed placebo-based randomize , control , trial .</brief_summary>
	<brief_title>Aberrations Carnitine Homeostasis Congenital Heart Disease With Increased Pulmonary Blood Flow</brief_title>
	<detailed_description>AIM : To pilot trial assess safety pharmacokinetics ( PK ) perioperative IV L-carnitine administration patient . To end , pilot clinical trial propose . Infants VSD AVSD undergo complete repair receive L-carnitine , one 3 dos ( 25 , 50 , 100 mg/kg , IV ) , prior CPB , 2 hr CPB . Serial blood sample obtain determine free , total , acylcarnitine level , plasma marker mitochondrial function , oxidative stress , bioavailable NO . Adverse event seek , clinical outcome assess . Study design : The inclusion exclusion criterion describe Aim 3A except infant VSD AVSD enrol ( TOF ) . The safety profile L-carnitine outstanding , report toxicity overdose reported113 . In fact , adverse reaction report transient nausea vomiting , less commonly gastritis . However , although rare , seizure report occur patient receive L-carnitine . Therefore , major adverse event monitor include evidence seizure activity GI bleeding . As per routine , patient suspect seizure monitor continuous EEG . Dosing well study child , particularly critically ill children67 , 114-116117 . In addition , effect CPB L-carnitine clearance child know . Therefore , major goal sub-aim establish pharmacokinetic profile L-carnitine patient population undergo surgery CPB , order move forward large randomize trial power efficacy prevention increase PVR post-bypass at-risk infant . Plasma concentration profile IV bolus dose adult describe two-compartmental model67 , 113 , 114 , 118 . Usual pediatric dose well delineate , recommendation include 50 mg/kg bolus follow infusion 50mg/kg/day , increase 300 mg/kg/day113 , 119 . Therefore , begin low dose ( 25 mg/kg ) , escalate dose group 5 . No intra-patient escalation allow dose escalated patient current dose level follow hospital discharge 30 day post-op safety PK data analyze . The DSMB approve dose escalation . The dose goal achieve normal supra-normal free carnitine level ( ~50 μmol/L ) low AC level ( ~3 μmol/L ) 24 hrs CPB ; period great risk pulmonary vascular morbidity .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Heart Septal Defects</mesh_term>
	<mesh_term>Heart Septal Defects , Ventricular</mesh_term>
	<mesh_term>Endocardial Cushion Defects</mesh_term>
	<criteria>unrestrictive VSD , AVSD undergo complete repair 212 month age correct gestational age ≥34 week indwell arterial venous line enteral parenteral nutrition least 6 hr body weight &lt; 2.0 kg pulmonary artery vein abnormality address surgically suspect proven inborn error metabolism major congenital abnormality affect cardiopulmonary system take carnitine supplementation</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>congenital heart disease</keyword>
	<keyword>ventricular septal defect</keyword>
	<keyword>atrioventricular septal defect</keyword>
	<keyword>increase pulmonary blood flow</keyword>
	<keyword>nitric oxide</keyword>
</DOC>